Robert Zeldin
Director Técnico/Científico/I+D en MEIRAGTX HOLDINGS PLC .
Fortuna: 422 600 $ al 30/04/2024
Cargos activos de Robert Zeldin
Empresas | Cargo | Inicio | Fin |
---|---|---|---|
MEIRAGTX HOLDINGS PLC | Director Técnico/Científico/I+D | 05/08/2020 | - |
Historial de carrera de Robert Zeldin
Antiguos cargos conocidos de Robert Zeldin.
Empresas | Cargo | Inicio | Fin |
---|---|---|---|
ACCELERON PHARMA INC. | Director Técnico/Científico/I+D | 05/07/2018 | 05/04/2019 |
STALLERGENES | Director Técnico/Científico/I+D | 01/01/2011 | 01/01/2015 |
Corporate Officer/Principal | 01/01/2011 | 01/01/2015 | |
IMMUNOVANT, INC. | Director Técnico/Científico/I+D | - | - |
Novartis Pharmaceuticals Corp.
Novartis Pharmaceuticals Corp. Pharmaceuticals: MajorHealth Technology Novartis Pharmaceuticals Corp. develops, manufactures, and markets prescription drugs. It manufactures and markets prescription drugs used to treat a number of diseases and conditions including cardiovascular, dermatological, central nervous system, bone disease, cancer, organ transplantation, psychiatry, infectious disease, and respiratory. The company was founded in 1996 and is headquartered in East Hanover, NJ. | Corporate Officer/Principal | - | - |
Center for Biologics Evaluation & Research
Center for Biologics Evaluation & Research Miscellaneous Commercial ServicesCommercial Services Center for Biologics Evaluation & Research engages in the regulation of biological and related products. Its scope includes blood, vaccines, allergenics, tissues, and cellular and gene therapies. The company is headquartered in Silver Spring, MD. | Director Técnico/Científico/I+D | - | - |
ABLYNX | Director Técnico/Científico/I+D | 01/12/2015 | - |
Formación de Robert Zeldin.
Tufts University School of Medicine | Doctorate Degree |
The Johns Hopkins University | Undergraduate Degree |
Estadísticas
Internacional
Estados Unidos | 8 |
Francia | 2 |
Bélgica | 2 |
Operativa
Chief Tech/Sci/R&D Officer | 6 |
Corporate Officer/Principal | 2 |
Doctorate Degree | 1 |
Sectorial
Health Technology | 7 |
Consumer Services | 3 |
Commercial Services | 2 |
Funciones ocupadas
Activas
Inactivas
Empresas cotizadas
Empresas privadas
Empresas relacionadas
Empresas cotizadas | 2 |
---|---|
IMMUNOVANT, INC. | Health Technology |
MEIRAGTX HOLDINGS PLC | Health Technology |
Empresas privadas | 5 |
---|---|
Stallergenes SA
Stallergenes SA Pharmaceuticals: MajorHealth Technology Stallergenes SA is an international biopharmaceutical company, which engages in the manufacture and sale of pharmaceutical products for the treatment of allergy-related respiratory diseases. The company operates through the Allergen Immunotherapy segment, which provides products and services for the desensitization of allergy-related respiratory conditions. Its products include a range of sublingual route and subcutaneous route products for the treatment of respiratory diseases such as rhino-conjunctivitis, rhinitis, and allergic asthma. Stallergenes was founded in 1962 and is headquartered in Antony, France. | Health Technology |
Ablynx NV
Ablynx NV BiotechnologyHealth Technology Ablynx NV operates as a clinical stage biopharmaceutical company, which engages in the development of proprietary therapeutic proteins under the Nanobodies brand. It includes haematology, inflammation, infectious disease, autoimmune disease, oncology and immune-oncology. The company was founded by Mark Vaeck in 2001 and is headquartered in Ghent, Belgium. | Health Technology |
Center for Biologics Evaluation & Research
Center for Biologics Evaluation & Research Miscellaneous Commercial ServicesCommercial Services Center for Biologics Evaluation & Research engages in the regulation of biological and related products. Its scope includes blood, vaccines, allergenics, tissues, and cellular and gene therapies. The company is headquartered in Silver Spring, MD. | Commercial Services |
Novartis Pharmaceuticals Corp.
Novartis Pharmaceuticals Corp. Pharmaceuticals: MajorHealth Technology Novartis Pharmaceuticals Corp. develops, manufactures, and markets prescription drugs. It manufactures and markets prescription drugs used to treat a number of diseases and conditions including cardiovascular, dermatological, central nervous system, bone disease, cancer, organ transplantation, psychiatry, infectious disease, and respiratory. The company was founded in 1996 and is headquartered in East Hanover, NJ. | Health Technology |
Acceleron Pharma, Inc.
Acceleron Pharma, Inc. BiotechnologyHealth Technology Acceleron Pharma, Inc. is a biopharmaceutical company, which engages in the discovery, development and commercialization of therapeutics to treat serious and rare diseases. Its product candidates include Luspatercept, designed to patients with chronic anemia associated within a wide range of blood diseases; ACE-083, designed for the treatment of focal muscle disorders; and Sotatercept, designed to treat pulmonary arterial hypertension. The company was founded by John L. Knopf and Thomas P. Maniatis in June 2003 and is headquartered in Cambridge, MA. | Health Technology |
- Bolsa de valores
- Insiders
- Robert Zeldin
- Experiencia